Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RBI-6000
- Development stage
- Preclinical
- Lead developer
- Replicate Bioscience
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**RBI-6000** is a wholly owned, preclinical **self-replicating RNA vaccine** being developed by Replicate Bioscience for prevention of respiratory infections caused by respiratory syncytial virus, human metapneumovirus, and parainfluenza viruses. The candidate uses Replicate's srRNA platform and is designed to express multiple viral antigens, with the aim of inducing protective immune responses against these respiratory pathogens.
02
Targets
Human parainfluenza virus antigensRSV G (Respiratory syncytial virus attachment glycoprotein)HMPV F (Human metapneumovirus fusion protein)
Beyond the preview
Go deeper on RBI-6000.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RBI-6000.